The Office of Fair Trading has accused pharmaceuticals giant GlaxoSmithKline of market "abuse".
The consumer watchdog alleged that Alpharma, Generics UK and Norton Healthcare, three of company’s competitors, received money to delay the commercialisation of their versions of GSK’s Seroxat, used to treat depression. GSK said it “supports fair competition” and that it “acted within the law”. In a statement, the firm said: “In fact, these arrangements actually…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login

